Michael Tallarico, MD
Medical Oncology · Dyer, INNPI 1467773036
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.1%), consulting fees and other — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Daiichi Sankyo Inc. at 25.6% of the total. Reporting peaked in 2024 at $9,493 and has fallen 59.2% since, to $3,874 in 2025.
Across 1,006 payments — averaging $35.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$9K
- AstraZeneca$7K
- Novartis$3K
- E.r. Squibb & Sons, L.L.C.$2K
- Bristol Myers Squibb$1K
- Merck$918
- plus $13K from 54 others
Across 1 payment — averaging $815.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$816
What the payments were for
- Consulting fees$13,79339%
- Speaking & faculty fees$1750%
- Food & beverage$19,11854%
- Education$7272%
- Other$1,5154%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$2,775
- Enhertu$2,360
- CALQUENCE$2,220
- DATROWAY$470
- ALIYA SYSTEM$185
- TECVAYLI$147
- TALVEY$147
- DARZALEX$147
- CARVYKTI$147
- SIR-Spheres Microspheres$146
- Monarch Platform$131
- Da Vinci Surgical System$126
- VERZENIO$110
How this compares
$35,328 in reported general payments places this provider in the 85th percentile of 67 medical oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 59 | $870,429 |
| XtandiEnzalutamide | 24 | $332,138 |
| JakafiRuxolitinib Phosphate | 17 | $284,897 |
| VenclextaVenetoclax | 35 | $245,653 |
| NubeqaDarolutamide | 16 | $209,816 |
| IbrancePalbociclib | 11 | $179,320 |
| CreonLipase/Protease/Amylase | 14 | $58,276 |
| EliquisApixaban | 47 | $47,703 |
| Abiraterone Acetate | 54 | $46,296 |
| Imatinib Mesylate | 49 | $44,974 |
| XareltoRivaroxaban | 36 | $29,643 |
| Posaconazole | 16 | $27,154 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $12,455 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 93 | $3,517 |
| Anastrozole | 168 | $2,867 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $6,516 | $870,42959 claims |
| Astellas Pharma US IncXtandi | $771 | $332,13824 claims |
| AbbVieVenclexta, Creon | $536 | $303,92849 claims |
| Incyte CorporationJakafi | $499 | $284,89717 claims |
| PfizerIbrance, Eliquis | $895 | $227,02358 claims |
| BayerNubeqa | $150 | $209,81616 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $147 | $46,29654 claims |
| Johnson & JohnsonXarelto | $654 | $29,64336 claims |
| GSKTrelegy Ellipta | $374 | $12,45514 claims |
| Lilly USA, LLCOlanzapine | $425 | $28941 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 67 medical oncology providers in Indiana.
Other medical oncology in Dyer
- Costantine AlbanyLafayette$212K
- Sunil BabuFort Wayne$166K
- Natraj AmmakkanavarIndianapolis$129K
- Rafat AnsariMishawaka$90K
- Bert OneilIndianapolis$89K
- Pablo BedanoIndianapolis$52K
- Gregory SmithIndianapolis$46K
- Ashwin VasudevamurthyIndianapolis$44K
- Eduardo BraunWestville$39K
- Daniel SonnenburgIndianapolis$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.